ProMIS Neurosciences (PMN) Jefferies Global Healthcare Conference 2026 summary

Corporate and financial overview

• Clinical-stage company focused on protein misfolding, with a strong financial position following a $75 million capital raise and potential for an additional $100 million upon data readout; cash runway extends through 2027.

• Leadership team includes seasoned experts in neurodegenerative diseases and drug discovery.

Technology platform and differentiation

• Proprietary EpiSelect platform uses computational modeling and AI to design antibodies highly selective for misfolded proteins, targeting 3D epitopes unique to toxic oligomers.

• Approach avoids off-target binding, aiming for improved efficacy and safety compared to conventional antibodies.

Clinical program and trial design

• Lead asset PMN310 targets toxic amyloid beta oligomers in Alzheimer's, avoiding plaque and monomers to reduce ARIA risk and improve efficacy.

• Phase I-A study in healthy volunteers showed strong safety, tolerability, and sufficient blood-brain barrier penetration.

• Ongoing placebo-controlled, double-blind, randomized phase Ib study in Alzheimer's patients at 22 U.S. sites, fully enrolled with 144 subjects, dosing monthly for 12 months.